A decade ago, a seminal study in the oropharyngeal cancer field1 reported that there had been a 225% increase in incidence of human papillomavirus (HPV)-associated oropharyngeal cancer in the US between 1988 and 2004. Crucially, the authors projected that if trends were to continue, HPV-positive oropharyngeal cancer would surpass cervical cancer as the leading HPV-associated cancer in the US by 2020.1 This prediction has since become a reality.2 Between 2012 and 2016, HPV-associated oropharyngeal cancer indeed became the most common HPV-associated cancer in the US, and its incidence has surpassed cervical cancer, the disease for which the HPV vaccine was first developed and marketed.3,4 In this issue of JAMA Otolaryngology–Head & Neck Surgery, the cross-sectional study by Damgacioglu and colleagues5 shines light on the trends in oropharyngeal cancer since the turn of the millennium using a relatively newly publicly available source of national data. They report that oropharyngeal cancer incidence increased nationally in the US between 2001 and 2017, especially among older adults.5